News
Biogen, Eisai double down on Alzheimer's with lecanemab fili...
Biogen and Eisai's first Alzheimer's disease drug Aduhelm is facing an uphill battle in the US market, but the partners are forging ahead with their second candidate lecanemab, starting a r
